<scp>CD70</scp> is a potential target biomarker in peripheral T‐cell lymphomas

Marques‐Piubelli, Mario L.; Sagert, Jason; Pham, Minh Thu; Will, Matthias Georg; Henderson, Dan Fenno; Tipton, Kimberly; Iyer, Swaminathan P.; Lü, Wei; Khan, Khaja; Hamana, Leticia; Chapman, Jennifer R.; Thakral, Beenu; Xu, Jie; Miranda, Roberto N.; Jennings, Kristofer; Solis, Luisa M.; Vega, Francisco

doi:10.1111/his.14670

Cited by 5 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We suggest that, similar to what has been shown in other cutaneous T-cell lymphomas, co-expression of CD70 and CD27 may represent an autoactivation loop driving oncogenic proliferation also in PCSM-LPD. Anti-CD70 antibodies have successfully been used to treat cutaneous T-cell lymphomas [16] as well as peripheral T-cell lymphomas [24] and may thus also be considered for PCSM-LPD when resection of the lesion is not feasible. The expression of immune-checkpoint molecules in combination with T-cell receptor activation in PCSM-LPD suggests that signals from the TME may play an important role in the pathogenesis of this disease.…”

Section: Discussionmentioning

confidence: 99%

CD27/CD70 pathway activation in primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder

Richter,

Oschlies,

Kock

et al. 2023

The Journal of Pathology

View full text Add to dashboard Cite

Primary cutaneous CD4+ small or medium T‐cell lymphoproliferative disorder (PCSM‐LPD) is a clonal T‐cell proliferation disease confined to the skin. PCSM‐LPD shares expression of T follicular helper (Tfh) cell markers with various mature T‐cell lymphomas. However, the benign presentation of PCSM‐LPD contrasts the clinical behavior of other Tfh‐lymphomas. The aim of our study was to delineate the molecular similarities and differences between PCSM‐LPD and other Tfh‐derived lymphomas to explain the clinical behavior and unravel possible pathological mechanisms. We performed targeted next‐generation sequencing of 19 genes recurrently mutated in T‐cell neoplasms in n = 17 PCSM‐LPD with high and in n = 21 PCSM‐LPD with low tumor cell content. Furthermore, gene expression profiling was used to identify genes potentially expressed in the PD1‐positive (PD1+) neoplastic cells. Expression of some of these genes was confirmed in situ using multistain immunofluorescence. We found that PCSM‐LPD rarely harbored mutations recurrently detected in other T‐cell neoplasms. PCSM‐LPD is characterized by the invariable expression of the T‐cell‐receptor‐associated LCK protein. CD70 and its ligand CD27 are co‐expressed on PD1+ PCSM‐LPD cells, suggestive of autoactivation of the CD70 pathway. In conclusion, PCSM‐LPD differs from disseminated lymphomas of Tfh origin by their mutation profile. Activation of CD70 signaling also found in cutaneous T‐cell lymphoma represents a potential driver of neoplastic proliferation of this benign neoplasia of Tfh. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

show abstract

Section: Discussionmentioning

confidence: 99%

CD27/CD70 pathway activation in primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder

Richter,

Oschlies,

Kock

et al. 2023

The Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…Median PFS and OS were 3.5 and 13.8 months, respectively [ 172 ]. Other early phase clinical trials have also explored CD70, a transmembrane protein member of the tumor necrosis factor superfamily, as a potential target in PTCL [ 173 ]. CD70 expression was demonstrated on various T-cell lymphomas on immunohistochemistry, including nodal PTCL subtypes such as PTCL-NOS and AITL.…”

Section: Immunotherapeuticsmentioning

confidence: 99%

Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma

Chang,

Tan,

Chan

2024

J Hematol Oncol

View full text Add to dashboard Cite

Peripheral T cell lymphoma (PTCL) represents a group of heterogeneous hematological malignancies, which are notoriously challenging to treat and outcomes are typically poor. Over the past two decades, clinical prognostic indices for patient risk stratification have evolved, while several targeted agents are now available to complement combination chemotherapy in the frontline setting or as a salvage strategy. With further understanding of the molecular pathobiology of PTCL, several innovative approaches incorporating immunomodulatory agents, epigenetic therapies, oncogenic kinase inhibitors and immunotherapeutics have come to the forefront. In this review, we provide a comprehensive overview of the progress in developing clinical prognostic indices for PTCL and describe the broad therapeutic landscape, emphasizing novel targetable pathways that have entered early phase clinical studies.

show abstract

“…CD70 belongs to the tumor necrosis factor superfamily (TNFSF) of transmembrane proteins, while CD27 is its receptor [ 79 ]. CD70 and CD27 could modulate the immune response by enhancing T and B cell activation, proliferation, and differentiation.…”

Section: Car-t Cell Therapy In Gbmmentioning

confidence: 99%

Gene Targets of CAR-T Cell Therapy for Glioblastoma

Wang

et al. 2023

Cancers

View full text Add to dashboard Cite

Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis following conventional therapeutic interventions. Moreover, the blood–brain barrier (BBB) severely impedes the permeation of chemotherapy drugs, thereby reducing their efficacy. Consequently, it is essential to develop novel GBM treatment methods. A novel kind of pericyte immunotherapy known as chimeric antigen receptor T (CAR-T) cell treatment uses CAR-T cells to target and destroy tumor cells without the aid of the antigen with great specificity and in a manner that is not major histocompatibility complex (MHC)-restricted. It has emerged as one of the most promising therapy techniques with positive clinical outcomes in hematological cancers, particularly leukemia. Due to its efficacy in hematologic cancers, CAR-T cell therapy could potentially treat solid tumors, including GBM. On the other hand, CAR-T cell treatment has not been as therapeutically effective in treating GBM as it has in treating other hematologic malignancies. CAR-T cell treatments for GBM have several challenges. This paper reviewed the use of CAR-T cell therapy in hematologic tumors and the selection of targets, difficulties, and challenges in GBM.

show abstract

CD70 is a potential target biomarker in peripheral T‐cell lymphomas

Cited by 5 publications

References 6 publications

CD27/CD70 pathway activation in primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder

CD27/CD70 pathway activation in primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder

Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma

Gene Targets of CAR-T Cell Therapy for Glioblastoma

Contact Info

Product

Resources

About